Randomized Trial of Vaccines for Zaire Ebola Virus Disease.

Mark Kieh,Laura Richert, Abdoul H Beavogui,Birgit Grund,Bailah Leigh,Eric D'Ortenzio,Seydou Doumbia, Edouard Lhomme, Samba Sow,Renaud Vatrinet,Céline Roy,Stephen B Kennedy,Sylvain Faye, Shelley Lees, Niouma P Millimouno,Alseny M Camara,Mohamed Samai,Gibrilla F Deen,Moussa Doumbia,Hélène Espérou,Jerome Pierson,Deborah Watson-Jones, Alpha Diallo,Deborah Wentworth,Chelsea McLean,Jakub Simon,Aurélie Wiedemann,Bonnie Dighero-Kemp, Lisa Hensley,H Clifford Lane,Yves Levy,Peter Piot, Brian Greenwood,Geneviève Chêne,James Neaton,Yazdan Yazdanpanah

The New England journal of medicine（2022）

引用 13|浏览36

暂无评分

摘要

No safety concerns were identified in this trial. With all three vaccine regimens, immune responses were seen from day 14 through month 12. (Funded by the National Institutes of Health and others; PREVAC ClinicalTrials.gov number, NCT02876328; EudraCT numbers, 2017-001798-18 and 2017-001798-18/3rd; and Pan African Clinical Trials Registry number, PACTR201712002760250.).

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要